Serul No

			X-15302	X-15302			10/575,815		
INFORMATION DISCLOSURE CITATION IN AN APPLICATION					First Applicant James Ronald Gillin				
IN AN AP	PLICAT	ION					-1-		
			International Filing Date: Ground October 21, 2004 1614						
			October 21, 2004			1014			
			US National Entry Date: April 14, 2006						
U.S. PA	TENT	DOCUMENTS							
Examiner Initials*	Cite	Document Number					of Patentee or		
	No. 1	Number-Kind Code ² (if incwn)		MM-M21111		Applicant of Cited Doonneat		Where Relevant Pager or Relevant Figures Appear	
	AA	US							
	AB	US							
	AC	US							
FOREI	GN PA	TENT DOCUMEN	rs						
Exactiner Intuits*	Clie No.1	Foreign Patent Document		Applic		Pulestee or c of Cited	Pages, Colonzas, La	Lines, Where	
		Country Code ³ -Number ⁴⁻ Kind Code5 (sf known)	M	M-DD-YYYY	Document		Reievani Passages or Reievant Figures Appear		
	BA	WO 01/21577		h 29, 2001	Takeda Chemical Industries Ltd.				
	BB	WO 03/097047	Nove 2003	mber 27,	Eli Lilly Compan				
	BC	WO 03/087046	Octo	ber 23, 2003	7TM Pharma				
		NON I	ATEN	T LITERAT	URE DOC	UMENTS			
Examener Initials*	Cite	Cite Include name of the nathor (in CAPITAL LETTERS), title of the stricle (when appropriate), title of the item No. 1 (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-assue number(s) publisher							T ⁶
	CA			city and/or countr	y where publ	ished.			
	CB							\rightarrow	
	CC							_	
	CD								
Examiner					Date Consi	idered			
Signature	and deather	no considered whether or not calcium as			-	the delay	discount and and assert	and Sandark or	

Atty Docket No.

FORM PTO 1449 (modified)

and on the construction of the construction of